Weatherly Asset Management L. P. Lowers stake in NuVasive (NUVA)

NuVasive (NUVA) : Weatherly Asset Management L. P. reduced its stake in NuVasive by 2.14% during the most recent quarter end. The investment management company now holds a total of 17,130 shares of NuVasive which is valued at $882,366 after selling 375 shares in NuVasive , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.NuVasive makes up approximately 0.30% of Weatherly Asset Management L. P.’s portfolio.

NuVasive opened for trading at $53.21 and hit $56.48 on the upside on Wednesday, eventually ending the session at $54.42, with a gain of 5.34% or 2.76 points. The heightened volatility saw the trading volume jump to 30,51,896 shares. Company has a market cap of $2,704 M.

Other Hedge Funds, Including , Strs Ohio sold out all of its stake in NUVA during the most recent quarter. The investment firm sold 5,200 shares of NUVA which is valued $267,852.Fisher Asset Management boosted its stake in NUVA in the latest quarter, The investment management firm added 7,182 additional shares and now holds a total of 1,410,780 shares of NuVasive which is valued at $72,669,278. NuVasive makes up approx 0.14% of Fisher Asset Management’s portfolio.Gemmer Asset Management reduced its stake in NUVA by selling 25 shares or 18.25% in the most recent quarter. The Hedge Fund company now holds 112 shares of NUVA which is valued at $5,685. Acadian Asset Management added NUVA to its portfolio by purchasing 106 company shares during the most recent quarter which is valued at $5,381. Dnb Asset Management As added NUVA to its portfolio by purchasing 71,600 company shares during the most recent quarter which is valued at $3,634,416. NuVasive makes up approx 0.07% of Dnb Asset Management As’s portfolio.

On the company’s financial health, NuVasive reported $0.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.27. The company had revenue of $215.10 million for the quarter, compared to analysts expectations of $205.44 million. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.

Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Company’s software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.

Leave a Reply

NuVasive - Is it time to Sell?

Top Brokerage Firms are advising their investors on NuVasive. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.